Long-term efficacy and safety of aromatase inhibitor use for leiomyomatosis peritonealis disseminata

J Obstet Gynaecol Res. 2017 Sep;43(9):1489-1492. doi: 10.1111/jog.13376. Epub 2017 Jul 10.

Abstract

Leiomyomatosis peritonealis disseminata is a rare disease characterized by pelvic smooth-muscle nodules of various sizes. It is sometimes misdiagnosed as ovarian or peritoneal carcinoma metastasis; therefore, surgical excision for pathological diagnosis is required. Treatment options include bilateral salpingo-oophorectomy (BSO), gonadotrophin-releasing hormone agonist therapy, and aromatase inhibitor therapy. All of these suppress estrogen levels, but a standard treatment has not been established. A 40-year-old woman had multiple pelvic tumors, suspicious for ovarian cancer. She underwent laparotomy, where frozen sections of the nodules revealed leiomyomatosis peritonealis disseminata. After she completed gonadotrophin-releasing hormone agonist therapy, we performed a total abdominal hysterectomy and BSO with residual-nodule resection, but the nodules recurred 6 months after surgery. We then started letrozole, and 3 years have now elapsed without nodule enlargement or development of new lesions. The long-term use of aromatase inhibitor therapy is thought to be effective and safe for patients with recurrence after BSO.

Keywords: aromatase inhibitor; estrogen; leiomyomatosis peritonealis disseminata; letrozole.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aromatase Inhibitors / administration & dosage
  • Aromatase Inhibitors / adverse effects
  • Aromatase Inhibitors / pharmacology*
  • Female
  • Humans
  • Leiomyomatosis / drug therapy*
  • Leiomyomatosis / surgery
  • Letrozole
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / surgery
  • Nitriles / administration & dosage
  • Nitriles / adverse effects
  • Nitriles / pharmacology*
  • Pelvic Neoplasms / drug therapy*
  • Pelvic Neoplasms / surgery
  • Peritoneal Cavity / pathology*
  • Peritoneal Cavity / surgery
  • Triazoles / administration & dosage
  • Triazoles / adverse effects
  • Triazoles / pharmacology*

Substances

  • Aromatase Inhibitors
  • Nitriles
  • Triazoles
  • Letrozole